Given that AMPK acts as an upstream effector of TAK1/NF-κB signaling, we next investigated whether targeting AMPK alone, or in combination with TAK1 suppression could inhibit the oncogenic capacities of ovarian cancer cells cultured in OCM. This evidence concerns the gene MAP3K7 and ovarian carcinoma.